Skip to main content
Advertising

Originally published Sunday, February 10, 2013 at 3:27 PM

  • Share:
           
  • Comments (0)
  • Print

Novo Nordisk says FDA rejects insulin drugs

Novo Nordisk AS says the Food and Drug Administration rejected its applications for approval of once-per-day insulin drugs to treat diabetes.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

NEW YORK —

Novo Nordisk AS says the Food and Drug Administration rejected its applications for approval of once-per-day insulin drugs to treat diabetes.

The Danish drugmaker says it received a "complete response letter" from the FDA regarding its applications for approval of Tresiba and Ryzodeg, or insulin degludec, on Friday. Such a letter indicates the agency determined the application cannot be approved in its current form.

In November, panel of federal health advisers recommended that the government approve degludec. The FDA is not required to follow the group's advice, but it often does.

Tresiba contains long-acting insulin, and Ryzodeg contains both long- and short-acting insulins.

Diabetics either do not produce enough of the hormone insulin or do not use it efficiently, allowing excess sugar, or glucose, to accumulate in the blood.

News where, when and how you want it

Email Icon

The Seattle Times photographs

Seattle space needle and mountains

Purchase The Seattle Times images


Advertising